NASDAQ:FRTX

Fresh Tracks Therapeutics (FRTX) Stock Price, News & Analysis

$0.92
-0.01 (-1.07%)
(As of 04/25/2024 ET)
Today's Range
$0.91
$0.92
50-Day Range
$0.87
$1.00
52-Week Range
$0.45
$1.10
Volume
422 shs
Average Volume
7,526 shs
Market Capitalization
$5.50 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
FRTX stock logo

About Fresh Tracks Therapeutics Stock (NASDAQ:FRTX)

Fresh Tracks Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops FRTX-02 (BBI-02), an oral DYRK1A inhibitor that is completed Phase 1 clinical trials for the treatment of autoimmune and inflammatory diseases; FRTX-10 (BBI-10), a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases; and FRTX-03, a topical DYRK1A inhibitor for the treatment of mild-to-moderate skin conditions, as well as next-generation kinase inhibitors. Fresh Tracks Therapeutics, Inc. has license and collaboration agreements with Carna Biosciences, Inc., and Voronoi Inc. The company was formerly known as Brickell Biotech, Inc. and changed its name to Fresh Tracks Therapeutics, Inc. in September 2022. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.

FRTX Stock Price History

FRTX Stock News Headlines

“Retirement Secret” Showed 995% Gain Last Time We Shared It
Central Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.
Fresh Tracks Therapeutics Inc
“Retirement Secret” Showed 995% Gain Last Time We Shared It
Central Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.
Fresh Tracks Therapeutics Inc FRTX
Fresh Tracks Therapeutics, Inc. (VCC.F)
8-K: Fresh Tracks Therapeutics, Inc.
See More Headlines
Receive FRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fresh Tracks Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/15/2024
Today
4/25/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:FRTX
Web
N/A
Employees
4
Year Founded
N/A

Profitability

Net Income
$-5,690,000.00
Pretax Margin
-71.12%

Debt

Sales & Book Value

Annual Sales
$8.01 million
Book Value
$1.66 per share

Miscellaneous

Free Float
5,959,000
Market Cap
$5.50 million
Optionable
Not Optionable
Beta
0.39
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Mr. Albert Nicholas Marchio II (Age 72)
    CEO, CFO, Secretary & Chairman
  • Aron Aizenstat M.B.A.
    P.M.P., Vice President of Corporate Development & Operations
  • Mr. Aaron Fox-Collis CPA
    VP of Finance & Chief Accounting Officer
  • Ms. Sue Fattor
    Head of Human Resource
  • Dr. James S. McElvain Ph.D.
    Interim Head of CMC Development

FRTX Stock Analysis - Frequently Asked Questions

How have FRTX shares performed in 2024?

Fresh Tracks Therapeutics' stock was trading at $0.8791 at the start of the year. Since then, FRTX stock has increased by 4.7% and is now trading at $0.9206.
View the best growth stocks for 2024 here
.

When is Fresh Tracks Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our FRTX earnings forecast
.

How were Fresh Tracks Therapeutics' earnings last quarter?

Fresh Tracks Therapeutics, Inc. (NASDAQ:FRTX) released its earnings results on Friday, March, 15th. The company reported ($0.20) earnings per share for the quarter. Fresh Tracks Therapeutics had a negative trailing twelve-month return on equity of 60.83% and a negative net margin of 91.29%.

How do I buy shares of Fresh Tracks Therapeutics?

Shares of FRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:FRTX) was last updated on 4/26/2024 by MarketBeat.com Staff

From Our Partners